These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23047788)

  • 21. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Takita Y; Goto T; Ichikawa H; Saito K; Matsumoto H; Tanaka Y
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):55-63. PubMed ID: 21265936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.
    Donnelly C; Bangs M; Trzepacz P; Jin L; Zhang S; Witte MM; Ball SG; Spencer TJ
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):176-85. PubMed ID: 20040824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial.
    Trzepacz PT; Spencer TJ; Zhang S; Bangs ME; Witte MM; Desaiah D
    Curr Med Res Opin; 2011; 27 Suppl 2():45-52. PubMed ID: 21973230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
    J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atomoxetine for attention deficit/hyperactivity disorder.
    Garces K
    Issues Emerg Health Technol; 2003 May; (46):1-4. PubMed ID: 12751480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atomoxetine's effect on societal costs in Sweden.
    Myrén KJ; Thernlund G; Nylén A; Schacht A; Svanborg P
    J Atten Disord; 2010 May; 13(6):618-28. PubMed ID: 19365087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder.
    Van Brunt DL; Johnston JA; Ye W; Pohl GM; Sun PJ; Sterling KL; Davis ME
    Pharmacotherapy; 2005 Nov; 25(11):1541-9. PubMed ID: 16232017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
    Saylor K; Williams DW; Schuh KJ; Wietecha L; Greenbaum M
    Curr Med Res Opin; 2010 Sep; 26(9):2087-95. PubMed ID: 20642391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder.
    Sert A; Gokcen C; Aypar E; Odabas D
    Cardiol Young; 2012 Apr; 22(2):158-61. PubMed ID: 21864451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing.
    Block SL; Kelsey D; Coury D; Lewis D; Quintana H; Sutton V; Schuh K; Allen AJ; Sumner C
    Clin Pediatr (Phila); 2009 Sep; 48(7):723-33. PubMed ID: 19420182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J; Gao H; Rogers AK; Spencer TJ
    Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effectiveness of strattera in children and adolescents with attention deficit hyperactivity disorder].
    Vakula IN; Vasianina IuSh; Gorbunova ZKh; Nikiforova EIu; Ponomarenko EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):42-4. PubMed ID: 19738568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
    Buitelaar JK; Michelson D; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
    Biol Psychiatry; 2007 Mar; 61(5):694-9. PubMed ID: 16893523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Electroencephalographic study of children with attention deficit hyperactivity disorder before and after treatment with strattera].
    Nikishina IS; Chutko LS; Surushina SIu; Iakovenko EA; Kropotov IuD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(12):60-2. PubMed ID: 19253469
    [No Abstract]   [Full Text] [Related]  

  • 39. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.
    Udvardi PT; Föhr KJ; Henes C; Liebau S; Dreyhaupt J; Boeckers TM; Ludolph AG
    Drug Des Devel Ther; 2013; 7():1433-46. PubMed ID: 24348020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication.
    Bradford WD; Kleit AN
    Health Econ; 2015 Jul; 24(7):859-75. PubMed ID: 25059655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.